ClinicalTrials.gov recorded primary completion on 2026-07-28 for bimekizumab in a phase 3 study of moderate to severe hidradenitis suppurativa. The trial, NCT04901195, enrolled 658 participants and is listed as active, not recruiting.
Background
The study evaluated bimekizumab in participants with hidradenitis suppurativa. The brief summary says the purpose was to evaluate the safety of long-term therapy in people with moderate to severe disease.
Trial design
According to the ClinicalTrials.gov record, this was a PHASE3 trial with 658 enrolled participants. The record identifies the condition as hidradenitis suppurativa and lists bimekizumab as the intervention.
What this means
Primary completion means the study reached the main data-collection milestone for its prespecified primary objective. For clinicians and researchers tracking hidradenitis suppurativa treatments, the completion status suggests long-term safety data for bimekizumab may be advancing through the trial process, but the posted record here does not include outcome results.
Source
This information is based on ClinicalTrials.gov trial record NCT04901195, with primary completion dated 2026-07-28. The record is available at clinicaltrials.gov.